Adding Vistusertib to Anastrozole Improves Safety and PFS in Patients with Endometrial Cancer
June 21st 2022Improvement in progression-free survival and safety demonstrated with the addition of vistusertib to anastrozole vs anastrozole alone in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
Triplet Combination Data Add Evidence to Clinical Activity in aRCC
June 16th 2022Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.
Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma
June 5th 2022Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.
Blocking TIGIT May Help With Dipping Remission Rates in NHL After CAR T-Cell Therapy
May 19th 2022In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.
PI3K Inhibitors and CAR T-Cell Therapy Find Their Niche in Indolent B-Cell Lymphomas
May 16th 2022In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.
Selinexor Showed Longer PFS Vs Placebo in Patients with Advanced, Metastatic DD-LPS
May 5th 2022Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.